



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	328301	METAGENICS BIO Q-ABSORB UBIQUINOL
ARTG entry for	Medicine Listed	
Sponsor	Metagenics (Aust) Pty Ltd	
Postal Address	PO Box 675, VIRGINIA BC, QLD, 4014 Australia	
ARTG Start Date	7/01/2020	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . METAGENICS BIO Q-ABSORB UBIQUINOL

Product Type	Single Medicine Product	Effective Date	24/03/2021
---------------------	-------------------------	-----------------------	------------

Permitted Indications

Antioxidant/Reduce free radicals formed in the body
Maintain/support energy levels
Maintain/support cardiovascular system health
Maintain/support heart health

Indication Requirements

Product presentation must not imply or refer to chronic fatigue syndrome.
Product presentation must not imply or refer to serious cardiovascular conditions.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

Do not take while on warfarin therapy without medical advice.
If symptoms persist consult your healthcare practitioner (or words to that effect).

Additional Product information

Pack Size/Poison information

Pack Size	Poison Schedule
------------------	------------------------

Components

1 . Formulation 1

Dosage Form	Capsule, soft
Route of Administration	Oral

Visual Identification



Australian Government
Department of Health
Therapeutic Goods Administration

Active Ingredients

ubiquinol-10 150 mg

Other Ingredients (Excipients)

Colour
d-alpha-tocopheryl acetate
Gelatin
glycerol
linoleic acid
medium chain triglycerides
Olive Oil
Orange Oil
PEG-35 castor oil
PEG-40 hydrogenated castor oil
polysorbate 80
purified water

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary